Entering text into the input field will update the search result below

Biotech Forum Daily Digest For The Ides Of March

Mar. 05, 2018 3:57 PM ETAIMT, CLSD, ITCI, NVS, SVRA, XNCR, MGNX, OTIC, ZBH21 Comments


  • The biotech sector will try to build on Friday's late rally that closed a losing week on an up note.
  • The FDA calendar is light this week.  Intra-Cellular Therapies will see if it can continue its rally this week after Buy ratings from a half dozen analyst firms.
  • All the other notable news, events and analyst ratings from across the sector and a Spotlight feature on Xencor are below.

There's a reason why golfers walk forward to their next shot. It's to move on.” ― J.R. Rim

It was another tough week for the market overall last week. Investors worried both about the potential for four quarter point hikes from the Federal Reserve in 2018. New concerns arose last week on the possibility of a 'trade war'.

All three major indices ended up in the red once again ek with the Dow having several days of triple digit declines. Fortunately, a deep early sell-off Friday was reversed by the end of the day. High beta sectors like biotech staged a nice intraday rally that kept losses lower for the week than they would have been. The main biotech indices rose over two percent to end a challenging week on a high note.

Author's note: To get these Biotech Forum Daily Digests as soon as they are published, just click here on my profile, hit the big orange "Follow" button, and choose the "real-time alerts" option.

Otonomy, Inc. (OTCPK:OTIC) disclosed Friday that the FDA has approved OTIPRIO for the treatment of acute otitis externa due to Pseudomonas aeruginosa and Staphylococcus aureus. OTIPRIO is the first single-dose antibacterial approved in the U.S. for the infection. Shares spiked initially but ended the day roughly flat as profit taking hit the stock.

There are a few presentations/study results that could have impacts on these small cap biotech stocks this week.

More data was released around Aimmune Therapeutics (AIMT) drug candidate's 'AR101' Phase 3 'PALISADE' trial. Initial data was release two weeks ago showing AR101 met its primary endpoint. Additional study results were disclosed at the American Academy of Allergy, Asthma & Immunology conference in Orlando Sunday. Our sister feed, The Insiders Forum just provided an in depth investment analysis on

This article was written by

Bret Jensen profile picture

Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha.  Our service offers a model 12 to 20 stock portfolio as well as Live Chat, weekly research and trade idea as well as market commentary and frequent portfolio updates.  

• • •

Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.

• • •

Learn more about Bret Jensen's Marketplace Offerings:

The Insiders Forum | The Biotech Forum | Busted IPO Forum

Analyst’s Disclosure: I am/we are long AIMT, ITCI, MGNX, OTIC, XNCR, ZBH. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (21)

Time for the MGNX rebound.
MGNX is ahead in the pipeline race for the CD123 CD3 mab with Xencor.
The bi-specifics mab sector has been great over the last 30 days.
Zymeworks, Genmab, Alligator Biosciences, MGNX, Xencor, Biomunex, and F-Star just to make a few bispecific companys.
Hi Bret, Any thoughts on the MGNX stock price going into the close for the setting of the secondary offering? Seems like the sell off is overdone.
Bret Jensen profile picture
has had big run....would add exposure via a Buy-Write if I was going to action
I guess that would be safer. The catalysts are mainly for 2019, expect for a 2H2018 Phase 1 Data for the dart CD123 candidate
Oh forgot this catalyst too. Looks like ESMO possibly for the presentations. Enoblituzumab (Fc-optimized anti-B7-H3 monoclonal antibody):
○ Complete enrollment of Phase 2 anti-PD-1 combination study (1H 2018), and
○ Present clinical data (2H 2018)
Savara stock is looking ripe for the taking. Especially in front of the Late Breaking Abstract for this weekend.
lookmil profile picture
Bret. Have you ever done any research on ChromaDex (CDXC) and their flagship product TruNiagen?
Bret Jensen profile picture
Hate that part of the sector frankly.
What are your thoughts about the SCYX offering when they already had plenty of cash?
Bret. What are your thoughts on SYnergy?
Bret Jensen profile picture
In regards to?
All of the above...earning, recent sales trend and what seems to be an ideological shift in Managment. I am truly optimistic again...if the numbers Steve up and break a 3k per week prior to June.
ALLCTT profile picture
Hi Bret, is SLS and ZYNE choice of yours too?
Bret Jensen profile picture
Have a piece of ZYNE
rowens72 profile picture
no mention of PGNX?
Bret Jensen profile picture
Can mention every single small cap biotech I like on every post, unfortunately
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.